[Association of functional genes polymorphisms of key enzymes in the metabolism of biogenic amines with paranoid schizophrenia susceptibility and the influence of these polymorphisms on PANSS results in antipsychotic treatment]

Psychiatr Pol. 2006 Sep-Oct;40(5):913-23.
[Article in Polish]

Abstract

Aim: The genetic components of the schizophrenia susceptibility are calculated as being 50%. We evaluated the frequency of alleles and genotypes of COMT and MAO-A genes polymorphisms in patients with schizophrenia and in the healthy population. We searched for the associations between genotypes and PANSS results among patients in a three month antipsychotic therapy.

Method: The study comprised 72 unrelated patients who met ICD-10 criteria for schizophrenia, and 187 unrelated healthy controls. The analysis of COMT and MAO-A genes polymorphisms were performed using the polymerase chain reaction technique (RFLP-restriction fragments length polymorphism and VNTR-variable number tandem repeats). The severity of psychopathological symptoms was measured by the PANSS (Positive and Negative Schizophrenia Scale).

Results: We did not find an association between the genotype of COMT and MAO-A genes polymorphisms and schizophrenia. We found statistically significant different allele distribution in MAO gene polymorphism: alleles with three tandem repeats in the promoter region were more frequent among females with schizophrenia. We did not find any association between the genotype of COMT and MAO-A genes polymorphisms and PANSS results in any time periods. Due to a small number of patients in this study the obtained results should be regarded as preliminary.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • Adult
  • Antipsychotic Agents / therapeutic use*
  • Carrier Proteins / genetics
  • Chi-Square Distribution
  • Female
  • Humans
  • Male
  • Membrane Glycoproteins / genetics
  • Polymorphism, Genetic*
  • Psychiatric Status Rating Scales
  • Quality of Life
  • Schizophrenia, Paranoid / drug therapy*
  • Schizophrenia, Paranoid / genetics*
  • Schizophrenic Psychology*
  • Severity of Illness Index

Substances

  • Antipsychotic Agents
  • Carrier Proteins
  • Membrane Glycoproteins